Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection
Journal of Labelled Compounds and Radiopharmaceuticals · 2018-07 · 61 (9) · 611-635
DOI: 10.1002/jlcr.3612 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, online erschienen am 30.03.2018. Verfasst von Lukas M Carter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Intact antibodies and their truncated counterparts (eg, Fab, scFv fragments) are generally exquisitely specific and selective vectors, enabling recognition of individual cancer‐associated molecular phenotypes against a complex and dynamic biomolecular background. Complementary alignment of these advantages with unique properties of radionuclides is a defining paradigm in both radioimmunoimaging and radioimmunotherapy, which remain some of the most adept and promising tools for cancer diagnosis and treatment. This review discusses how translational potency can be maximized through rational selection of antibody‐nuclide couples for radioimmunoimaging/therapy in preclinical models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Departments of Radiology and Pharmacology, Weill Cornell Medical College, New York, New York, USA.
- Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Sophie Poty, Sai Kiran Sharma, Jason S Lewis
Förderung
- NIBIB NIH HHS
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Carter, L. M., Poty, S., Sharma, S. K., & Lewis, J. S. (2018). Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals, 61(9), 611-635. https://doi.org/10.1002/jlcr.3612
Vancouver
Carter LM, Poty S, Sharma SK, Lewis JS. Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection. Journal of Labelled Compounds and Radiopharmaceuticals. 2018;61(9):611-635. doi:10.1002/jlcr.3612
BibTeX
@article{Carter2018,
author = {Carter, Lukas M and Poty, Sophie and Sharma, Sai Kiran and Lewis, Jason S},
title = {Preclinical optimization of antibody‐based radiopharmaceuticals for cancer imaging and radionuclide therapy—Model, vector, and radionuclide selection},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2018},
volume = {61},
number = {9},
pages = {611--635},
doi = {10.1002/jlcr.3612}
}
EUVIMED